Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:GLYC's Cash to Debt is ranked higher than
76% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:GLYC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:GLYC' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
NAS:GLYC's Interest Coverage is ranked higher than
66% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:GLYC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:GLYC' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: 11.04
M-Score: -101.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -158.08
NAS:GLYC's Operating margin (%) is ranked lower than
56% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:GLYC: -158.08 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:GLYC' s Operating margin (%) Range Over the Past 10 Years
Min: -265.61  Med: -74.13 Max: 23.83
Current: -158.08
-265.61
23.83
Net-margin (%) -157.83
NAS:GLYC's Net-margin (%) is ranked lower than
57% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:GLYC: -157.83 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:GLYC' s Net-margin (%) Range Over the Past 10 Years
Min: -265.61  Med: -74.01 Max: 23.96
Current: -157.83
-265.61
23.96
ROE (%) -69.45
NAS:GLYC's ROE (%) is ranked lower than
71% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:GLYC: -69.45 )
Ranked among companies with meaningful ROE (%) only.
NAS:GLYC' s ROE (%) Range Over the Past 10 Years
Min: -137.43  Med: -41.42 Max: 34.84
Current: -69.45
-137.43
34.84
ROA (%) -60.29
NAS:GLYC's ROA (%) is ranked lower than
75% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:GLYC: -60.29 )
Ranked among companies with meaningful ROA (%) only.
NAS:GLYC' s ROA (%) Range Over the Past 10 Years
Min: -89.49  Med: -24.15 Max: 15.45
Current: -60.29
-89.49
15.45
ROC (Joel Greenblatt) (%) -968.23
NAS:GLYC's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:GLYC: -968.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:GLYC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2627.95  Med: -1944.15 Max: 1059.77
Current: -968.23
-2627.95
1059.77
» NAS:GLYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

GLYC Guru Trades in Q3 2015

Jim Simons 47,800 sh (-19.39%)
» More
Q4 2015

GLYC Guru Trades in Q4 2015

Jim Simons 60,921 sh (+27.45%)
» More
Q1 2016

GLYC Guru Trades in Q1 2016

Jim Simons 69,200 sh (+13.59%)
» More
Q2 2016

GLYC Guru Trades in Q2 2016

Paul Tudor Jones 55,000 sh (New)
Jim Simons 114,600 sh (+65.61%)
» More
» Details

Insider Trades

Latest Guru Trades with GLYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:EVGN, OTCPK:CTIX, NAS:CDTX, NAS:AGTC, NAS:DPRX, NAS:IMDZ, NAS:ATHX, NAS:PRTO, AMEX:SYN, NAS:ADVM, NAS:NYMX, NAS:ENZY, OTCPK:SIGA, NAS:GNCA, NAS:CDXS, NAS:MDWD, NAS:OCUL, NAS:PRQR, NAS:MRUS, NAS:KMDA » details
Traded in other countries:GKO.Germany,
GlycoMimetics Inc is a clinical stage biotechnology company. The Company is engaged in discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.

Ratios

vs
industry
vs
history
Forward P/E 6.06
GLYC's Forward P/E is ranked higher than
91% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. GLYC: 6.06 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.12
GLYC's P/B is ranked higher than
55% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. GLYC: 3.12 )
Ranked among companies with meaningful P/B only.
GLYC' s P/B Range Over the Past 10 Years
Min: 1.81  Med: 2.78 Max: 5.3
Current: 3.12
1.81
5.3
P/S 3360.00
GLYC's P/S is ranked lower than
99% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. GLYC: 3360.00 )
Ranked among companies with meaningful P/S only.
GLYC' s P/S Range Over the Past 10 Years
Min: 3.94  Med: 10.02 Max: 4485
Current: 3360
3.94
4485
Current Ratio 8.95
GLYC's Current Ratio is ranked higher than
74% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. GLYC: 8.95 )
Ranked among companies with meaningful Current Ratio only.
GLYC' s Current Ratio Range Over the Past 10 Years
Min: 2.14  Med: 8.32 Max: 21.83
Current: 8.95
2.14
21.83
Quick Ratio 8.95
GLYC's Quick Ratio is ranked higher than
74% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. GLYC: 8.95 )
Ranked among companies with meaningful Quick Ratio only.
GLYC' s Quick Ratio Range Over the Past 10 Years
Min: 2.14  Med: 8.32 Max: 21.83
Current: 8.95
2.14
21.83
Days Sales Outstanding 11.13
GLYC's Days Sales Outstanding is ranked higher than
86% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. GLYC: 11.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLYC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.53  Med: 0.62 Max: 11.13
Current: 11.13
0.53
11.13

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.34
GLYC's Price/Net Cash is ranked higher than
72% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. GLYC: 3.34 )
Ranked among companies with meaningful Price/Net Cash only.
GLYC' s Price/Net Cash Range Over the Past 10 Years
Min: 2.29  Med: 3.15 Max: 5.59
Current: 3.34
2.29
5.59
Price/Net Current Asset Value 3.25
GLYC's Price/Net Current Asset Value is ranked higher than
71% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. GLYC: 3.25 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GLYC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.25  Med: 2.79 Max: 5.54
Current: 3.25
2.25
5.54
Price/Tangible Book 3.17
GLYC's Price/Tangible Book is ranked higher than
63% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. GLYC: 3.17 )
Ranked among companies with meaningful Price/Tangible Book only.
GLYC' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.19  Med: 2.72 Max: 5.49
Current: 3.17
2.19
5.49
Price/Median PS Value 336.00
GLYC's Price/Median PS Value is ranked lower than
100% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. GLYC: 336.00 )
Ranked among companies with meaningful Price/Median PS Value only.
GLYC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.56  Med: 0.95 Max: 363.5
Current: 336
0.56
363.5
Earnings Yield (Greenblatt) (%) -31.14
GLYC's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. GLYC: -31.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLYC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -57.31  Med: 0 Max: 0
Current: -31.14
-57.31
0

More Statistics

Revenue (TTM) (Mil) $20.07
EPS (TTM) $ -1.66
Short Percentage of Float8.91%
52-Week Range $3.70 - 9.25
Shares Outstanding (Mil)23.06

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 60 50 41
EPS ($) -1.77 1.18 0.62 0.09
EPS w/o NRI ($) -1.77 1.18 0.62 0.09
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:GLYC

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
GLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 23 2016
GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple... Sep 14 2016
GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple... Sep 14 2016
Glycomimetics Joins New Sickle Cell Disease Coalition, Issues Call to Action to Improve Treatment... Sep 09 2016
GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 Sep 06 2016
GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 Sep 06 2016
GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces... Aug 16 2016
GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces... Aug 16 2016
GlycoMimetics Initiated At Outperform By Cowen And Company Aug 15 2016
GLYCOMIMETICS INC Financials Aug 12 2016
GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference Aug 08 2016
Zacks.com featured highlights: GlycoMimetics, Lion Biotechnologies, AMN Healthcare Services,... Aug 05 2016
GlycoMimetics reports 2Q loss Aug 04 2016
GlycoMimetics reports 2Q loss Aug 04 2016
GlycoMimetics Reports Second Quarter 2016 Results Aug 04 2016
GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2016
GlycoMimetics Reports Second Quarter 2016 Results Aug 04 2016
GLYCOMIMETICS INC Files SEC form 10-Q, Quarterly Report Aug 04 2016
Coverage initiated on GlycoMimetics by SunTrust Jul 26 2016
GlycoMimetics Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly... Jun 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)